© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
June 27, 2022
The lower energy applications and slower sweep speeds offer marked IOP reductions in patients.
June 25, 2022
A team of investigators from the Yong Loo Lin School of Medicine at the National University of Singapore has found that there is a bidirectional association between chronic kidney disease and glaucoma.
June 12, 2022
The research is the result of a national collaboration led by investigators from the Centre for Eye Research Australia at the University of Melbourne and University of Tasmania and the Garvan Institute of Medical Research.
June 11, 2022
According to the company, no safety concerns with corneal endothelial health reported across all 3 trials, and the device delivered consistent results up to two-year follow-up in patients across Central and South America, Asia and Europe.
May 24, 2022
Presented at ARVO 2022, research from Mass Eye and Ear hopes to open a new avenue for therapies that are for helping treat patients that develop primary open angle glaucoma.
May 17, 2022
Two grants will be available, each offering $150,000 to scientists focusing on glaucoma research who have already received their first independent federal National Institutes of Health (NIH) grant and are collecting new and novel data to apply for a second R01.
March 09, 2022
A complete understanding can help ophthalmologists get better results for their patients.
March 08, 2022
A recent study of cannabinol in in vitro and in vivo glaucoma models, demonstrated encouraging results that may address some of the previous challenges associated with cannabis use and may present a new potential therapeutic intervention in the treatment of glaucoma.
March 04, 2022
In advance of World Glaucoma Week March 6-12, a study of 3826 patients with glaucoma has found significantly higher odds of self-reported difficulty affording medication observed among non-Hispanic African American and Hispanic individuals compared with non-Hispanic White individuals.
March 03, 2022
The company’s new technology, which targets the eye’s conventional outflow pathway, is expected to have full commercial availability on April 1.